Tocilizumab Reduces Hypercoagulation in COVID-19 – Perspectives from The Coagulation and Immunomodulation Covid Assessment (Coag- ImmCovA) Clinical Trial
View ORCID ProfileLou M. Almskog, Anna Sjöström, Jonas Sundén-Cullberg, Apostolos Taxiarchis, Anna Ågren, Sara Freyland, Madeleine Börjesson, Agneta Wikman, Carl Magnus Wahlgren, Michael Wanecek, Jan van der Linden, Jovan Antovic, Jon Lampa, Maria Magnusson
doi: https://doi.org/10.1101/2024.05.31.24308108
Lou M. Almskog
1Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
2Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden
Anna Sjöström
1Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
3Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden
Jonas Sundén-Cullberg
4Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
5Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden
Apostolos Taxiarchis
1Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
3Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden
Anna Ågren
1Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
6Department of Clinical Sciences, Danderyd Hospital, Division of Cardiovascular Medicine, Karolinska Institutet, Stockholm, Sweden
7Coagulation Unit, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
Sara Freyland
8Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Madeleine Börjesson
2Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden
Agneta Wikman
9Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden
10Department of Center for Hematology and Regenerative Medicine (HERM), Karolinska Institutet, Stockholm, Sweden
Carl Magnus Wahlgren
1Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
11Department of Vascular Surgery, Karolinska University Hospital, Stockholm, Sweden
Michael Wanecek
12Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
13Intensive Care Unit, Capio St Göran’s Hospital, Stockholm, Sweden
Jan van der Linden
12Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Jovan Antovic
1Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
3Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden
Jon Lampa
14Rheumatology Division, Department of Medicine Solna, Center for Molecular Medicine (CMM), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Maria Magnusson
1Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
7Coagulation Unit, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
15Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted June 10, 2024.
Tocilizumab Reduces Hypercoagulation in COVID-19 – Perspectives from The Coagulation and Immunomodulation Covid Assessment (Coag- ImmCovA) Clinical Trial
Lou M. Almskog, Anna Sjöström, Jonas Sundén-Cullberg, Apostolos Taxiarchis, Anna Ågren, Sara Freyland, Madeleine Börjesson, Agneta Wikman, Carl Magnus Wahlgren, Michael Wanecek, Jan van der Linden, Jovan Antovic, Jon Lampa, Maria Magnusson
medRxiv 2024.05.31.24308108; doi: https://doi.org/10.1101/2024.05.31.24308108
Tocilizumab Reduces Hypercoagulation in COVID-19 – Perspectives from The Coagulation and Immunomodulation Covid Assessment (Coag- ImmCovA) Clinical Trial
Lou M. Almskog, Anna Sjöström, Jonas Sundén-Cullberg, Apostolos Taxiarchis, Anna Ågren, Sara Freyland, Madeleine Börjesson, Agneta Wikman, Carl Magnus Wahlgren, Michael Wanecek, Jan van der Linden, Jovan Antovic, Jon Lampa, Maria Magnusson
medRxiv 2024.05.31.24308108; doi: https://doi.org/10.1101/2024.05.31.24308108
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (669)
- Anesthesia (181)
- Cardiovascular Medicine (2650)
- Dermatology (223)
- Emergency Medicine (400)
- Epidemiology (12234)
- Forensic Medicine (10)
- Gastroenterology (760)
- Genetic and Genomic Medicine (4109)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2661)
- Health Policy (1005)
- Hematology (364)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (439)
- Neurology (3890)
- Nursing (210)
- Nutrition (578)
- Oncology (2037)
- Ophthalmology (585)
- Orthopedics (241)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1116)
- Primary Care Research (452)
- Public and Global Health (6536)
- Radiology and Imaging (1407)
- Respiratory Medicine (871)
- Rheumatology (410)
- Sports Medicine (343)
- Surgery (450)
- Toxicology (53)
- Transplantation (185)
- Urology (166)